Daytime Severe Cold And Flu

Daytime Severe Cold And Flu Manufacturers

• Humanwell Puracap Pharmaceutical (Wuhan), Ltd.
  

  ×

  Daytime Severe Cold And Flu | Humanwell Puracap Pharmaceutical (wuhan), Ltd.

  

  ---

  take only as directed - see Overdose warning do not exceed 4 doses per 24 hours

  adults & children 12 years of age and over

  2 softgels with water every 4 hours

  children 4 to under 12 years of age

  ask a doctor

  children under 4 years of age

  do not use

  when using other Nighttime or Daytime products, carefully read each label to ensure correct dosing

  Close
  No Recall

  More Info
• Kroger Company
  

  ×

  Daytime Severe Cold And Flu | Basiem

  

  ---

  DOSAGE AND ADMINISTRATION:

  Carefully consider the potential benefits and risks of naproxen tablets, USP and other treatment options before deciding to use naproxen tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
  After observing the response to initial therapy with naproxen tablets, USP, the dose and frequency should be adjusted to suit an individual patient’s needs.

  Different dose strengths and formulations (i.e., tablets, suspension) of the drug are not necessarily bioequivalent. This difference should be taken into consideration when changing formulation.

  Although naproxen tablets, USP, naproxen suspension, naproxen delayed-release tablets, and naproxen sodium tablets all circulate in the plasma as naproxen, they have pharmacokinetic differences that may affect onset of action. Onset of pain relief can begin within 1 hour in patients taking naproxen.

  The recommended strategy for initiating therapy is to choose a formulation and a starting dose likely to be effective for the patient and then adjust the dosage based on observation of benefit and/or adverse events. A lower dose should be considered in patients with renal or hepatic impairment or in elderly patients (see WARNINGS and PRECAUTIONS).

  Geriatric Patients
  Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose.

  Patients With Moderate to Severe Renal Impairment
  Naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance <30 mL/min) (see WARNINGS: Renal Effects).

  Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: Naproxen Tablets, USP 500 mg twice daily

  During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. The morning and evening doses do not have to be equal in size and the administration of the drug more frequently than twice daily is not necessary.
  In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/day for limited periods of up to 6 months when a higher level of antiinflammatory/analgesic activity is required. When treating such patients with naproxen 1500 mg/day, the physician should observe sufficient increased clinical benefits to offset the potential increased risk. The morning and evening doses do not have to be equal in size and administration of the drug more frequently than twice daily does not generally make a difference in response (see CLINICAL PHARMACOLOGY).

  Acute Gout
  The recommended starting dose is 750 mg of naproxen tablets, USP followed by 250 mg every 8 hours until the attack has subsided.

  DOSAGE AND ADMINISTDRATION

  Apply MaC Patch to intact skin to cover the area most sensitive to pain. Each patch should not be applied for more than 8 hours in a given 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner. Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.

  If irritation or a burning sensation occurs during application, remove the patch and do not reapply until the irritation subsides. When MaC Patch is used concomitantly with other products containing same or similar agents, the amount absorbed from all formulations must be considered

  Close
  No Recall

  More Info
• Kroger Company
  

  ×

  Daytime Severe Cold And Flu | American Health Packaging

  

  ---

  Adult Administration

  The optimal dose of Doxercalciferol Capsules must be carefully determined for each patient. Table 4 provides the current recommended therapeutic target levels for iPTH in patients with chronic kidney disease:

  Table 4: Target Range of Intact Plasma PTH by Stage of CKD

  CKD Stage

  GFR (mL/min/1.73 m2)

  Target "intact" PTH (pg/mL)

  3

  30 to 59

  35 to 70

  4

  15 to 29

  70 to 110

  5

  <15 (or dialysis)

  150 to 300

  From Table 15 of National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S202, 2003 (suppl 3)

  Dialysis

  The recommended initial dose of Doxercalciferol Capsules is 10 mcg administered three times weekly at dialysis (approximately every other day). The initial dose should be adjusted, as needed, in order to lower blood iPTH into the range of 150 to 300 pg/mL. The dose may be increased at 8-week intervals by 2.5 mcg if iPTH is not lowered by 50% and fails to reach the target range. The maximum recommended dose of doxercalciferol is 20 mcg administered three times a week at dialysis for a total of 60 mcg per week. Drug administration should be suspended if iPTH falls below 100 pg/mL and restarted one week later at a dose that is at least 2.5 mcg lower than the last administered dose. During titration, iPTH, serum calcium, and serum phosphorus levels should be obtained weekly. If hypercalcemia, hyperphosphatemia, or a serum calcium times serum phosphorus product greater than 55 mg2/dL2 is noted, the dose of Doxercalciferol Capsules should be decreased or suspended and/or the dose of phosphate binders should be appropriately adjusted. If suspended, the drug should be restarted at a dose that is at least 2.5 mcg lower.

  Dosing must be individualized and based on iPTH levels with monitoring of serum calcium and serum phosphorus levels. The following is a suggested approach in dose titration:

  Table 5: Dialysis Dosing Recommendations

  Initial Dosing

  iPTH Level

  Doxercalciferol Dose

  >400 pg/mL

  10 mcg three times per week at dialysis

  Dose Titration

  iPTH Level

  Doxercalciferol Dose

  Above 300 pg/mL

  Increase by 2.5 mcg at eight-week intervals as necessary

  150 to 300 pg/mL

  Maintain

  <100 pg/mL

  Suspend for one week, then resume at a dose that is at least 2.5 mcg lower

  Pre-Dialysis

  The recommended initial dose of Doxercalciferol Capsules is 1 mcg administered once daily. The initial dose should be adjusted, as needed, in order to lower blood iPTH to within target ranges (see table below). The dose may be increased at 2-week intervals by 0.5 mcg to achieve the target range of iPTH. The maximum recommended dose of Doxercalciferol Capsules is 3.5 mcg administered once per day.

  Serum levels of calcium and phosphorus and plasma levels of iPTH should be monitored at least every two weeks for 3 months after initiation of Doxercalciferol Capsules therapy or following dose adjustments in Doxercalciferol Capsules therapy, then monthly for 3 months, and every 3 months thereafter. If hypercalcemia, hyperphosphatemia, or a serum calcium times phosphorus product greater than 55 mg2/dL2 is noted, the dose of Doxercalciferol Capsules should be decreased or suspended and/or the dose of phosphate binders should be appropriately adjusted. If suspended, the drug should be restarted at a dose that is at least 0.5 mcg lower.

  Dosing must be individualized and based on iPTH levels with monitoring of serum calcium and serum phosphorus levels. Table 6 presents a suggested approach in dose titration:

  Table 6: Pre-Dialysis Dosing Recommendations

  Initial Dosing

  iPTH Level

  Doxercalciferol Dose

  >70 pg/mL (Stage 3)

  1 mcg once per day

  >110 pg/mL (Stage 4)

  Dose Titration

  iPTH Level

  Doxercalciferol Dose

  Above 70 pg/mL (Stage 3)

  Increase by 0.5 mcg at two-week intervals as necessary

  110 pg/mL (Stage 4)

  35 to 70 pg/mL (Stage 3)

  Maintain

  70 to 110 pg/mL (Stage 4)

  <35 pg/mL (Stage 3)

  Suspend for one week, then resume at a dose that is at least 0.5

  <70 pg/mL (Stage 4)

  mcg lower

  Close
  No Recall

  More Info